Kinnate Biopharma Inc. (KNTE)

Market Cap	258.93M
Revenue (ttm)	n/a
Net Income (ttm)	-116.27M
Shares Out	46.57M
EPS (ttm)	-2.64
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	91,893
Open	5.70
Previous Close	5.76
Day's Range	5.35 - 5.70
52-Week Range	3.30 - 15.86
Beta	0.19
Analysts	Buy
Price Target	29.29 (+426.8%)
Earnings Date	May 11, 2023

About KNTE

Kinnate Biopharma Inc., a biopharmaceutical company, focuses on the discovery and development of small molecule kinase inhibitors to treat genomically defined cancers in the United States. The company develops KIN-2787, a rapidly accelerated fibrosarcoma inhibitor for the treatment of patients with lung cancer, melanoma, and other solid tumors; KIN-3248 small-molecule kinase inhibitors that target cancer-associated alterations in fibroblast growth factor receptors FGFR2 and FGFR3 genes; and small molecule research programs, including Cyclin-Dep...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Dec 3, 2020
• Employees: 86
• Stock Exchange: NASDAQ
• Ticker Symbol: KNTE

Analyst Forecast

According to 14 analysts, the average rating for KNTE stock is "Buy." The 12-month stock price forecast is $29.29, which is an increase of 426.80% from the latest price.

Price Target

$29.29

(426.80% upside)

Analyst Consensus: Buy